Glutathione
39,00 €
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Comprehensive reduction of oxidative stress.
- Improved Phase II hepatic detoxification.
- Supports the immune system.
- Skin lightening through the inhibition of melanin synthesis.
- Neuroprotection in Parkinson’s disease and other degenerative conditions.
- Improving Insulin Sensitivity in Metabolic Research.
Description
Glutathione
Antioxidant / Detox / Immune
MECHANISM OF ACTION
Endogenous tripeptide (γ-Glu-Cys-Gly). Master antioxidant: directly neutralizes reactive oxygen species, regenerates vitamins C and E, and maintains the redox balance of thiols. Cofactor for detoxifying enzymes such as glutathione peroxidase and S-transferase. Regulates T-cell proliferation and NK-cell activity. Inhibits ferroptosis.
KEY BENEFITS
- Comprehensive reduction of oxidative stress.
- Improved Phase II hepatic detoxification.
- Supports the immune system.
- Skin lightening through the inhibition of melanin synthesis.
- Neuroprotection in Parkinson’s disease and other degenerative conditions.
- Improving Insulin Sensitivity in Metabolic Research.
SIDE EFFECTS AND SAFETY
IV: rare allergic reactions and possible zinc depletion with prolonged use. SubQ: discomfort at the injection site. Oral supplementation is largely broken down in the gastrointestinal tract; parenteral forms are significantly more effective.
RESEARCH AND CLINICAL NOTES
Extensive literature. Intravenous glutathione for Parkinson’s disease: Mischley 2017 reported a reduction in motor symptoms. Skin lightening: A randomized clinical trial showed a significant reduction in melanin with 500 mg/day. Its fundamental role in cellular and immune redox function is well established.
TARGET PROFILE:
IV therapy protocols, integrative medicine, aesthetic treatments focused on skin lightening, and detox programs.
Additional information
| Weight | ,26 kg |
|---|
Ingredients and Nutrition
Ingredient 1 - cucumber extract
Ingredient 2 - bilberry extract
Indications
1 capsule in the morning
You may also like…
Hot
Algal Oil Omega 3 EPA/DHA, 100 capsules
- Vegan source of Omega-3: Schizochytrium microalgae oil, a sustainable alternative to fish oil.
- Cardiovascular health: DHA and EPA help reduce triglycerides, improve circulation, and control blood pressure.
- Brain and cognitive wellness: Supports memory, concentration, and prevents cognitive decline.
- Eye health: DHA is an essential component of the retina, helping maintain optimal vision.
- Anti-inflammatory properties: Alleviates symptoms of arthritis and other chronic inflammatory diseases.
- Suitable for vegans: Free from gluten, lactose, and preservatives.
Related products
New
BPC 157
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Accelerated healing of tendons, ligaments, muscles, and connective tissue.
- Protection of the gastrointestinal mucosa and support for ulcer healing.
- Neuroprotection and peripheral nerve regeneration.
- Powerful anti-inflammatory action through the suppression of pro-inflammatory cytokines.
- Systemic cytoprotective effects on multiple organ systems.
- Benefits at SNC: Research on depression, PTSD, and addictive behavior.
New
BPC 5 mg + TB 5 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Faster soft tissue repair than with any of the peptides alone.
- Coverage for localized repair (BPC-157) and systemic repair (TB-500).
- Reduction of inflammation and pain following an injury.
- Recovery of joints, tendons, ligaments, and muscles.
- A convenient, single-vial protocol for injury recovery.
CJC-1295 without DAC
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Physiological pattern of pulsatile GH secretion.
- Lower risk of desensitization compared to the DAC version.
- Improved body composition and recovery.
- Improved sleep quality, with synergistic effects when taken at night.
- Suitable for use in combination with GHRP-class peptides.
New
DSIP
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Improved sleep quality, especially deep, slow-wave (delta) sleep.
- Stress-reducing and anxiolytic effects.
- Normalization of disrupted sleep patterns.
- Potential application in opioid/alcohol withdrawal syndrome.
- Geroprotector: Anticancer Properties in Animal Models.
New
GHK-Cu
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- A significant increase in collagen synthesis and improved skin firmness.
- Accelerated healing and reduced scarring.
- Stimulation of the hair follicle and improvement in hair density.
- Systemic anti-aging effect through modulation of gene expression.
- Systemic antioxidant and anti-inflammatory action.
- Bone Regeneration and Nerve Repair in Research Models.
New
Retatrutide 10 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
New
Semaglutide
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Average body weight reduction of 15–17% with 2.4 mg per week.
- A 1.5–2.0% reduction in HbA1c.
- A 20% reduction in MACE in the SELECT trial among an obese, non-diabetic population.
- Remission of NASH in clinical trials.
- Reduced cravings for substances and alcohol, according to emerging data.
- Potential cognitive protection in dementia research.
New
Tesamorelin
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- FDA Approves Treatment to Reduce Visceral Fat Associated with HIV.
- Significant reduction in visceral fat in clinical trials.
- Improvement in lipid profile and metabolic health.
- Preservation of GH's natural pulsatile physiology.
- Cognitive Benefits: IGF-1 Modulation in Research on Mild Cognitive Impairment.
